Tmtrx, Inc.

Yacolt, WA

UEI
VW2EHP9XKZ33
CAGE
8PB32
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Hispanic American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
22482 NE Steelhead Ln, Yacolt, WA 98675, USA
Website
tmt-rx.com

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments… R44DA056267 National Institute on Drug Abuse (NIH) $4,804,558
Development of therapeutics to treat fentanyl overdose using a validated animal model R41DA055409 National Institute on Drug Abuse (NIH) $1,123,908

Quick answers

Is Tmtrx, Inc. registered in SAM.gov?

Yes. Tmtrx, Inc.'s SAM.gov registration is active through December 30, 2026.

What is Tmtrx, Inc.'s most recent federal award?

Tmtrx, Inc.'s most recent federal grant award is Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments… (R44DA056267), from National Institute on Drug Abuse (NIH), on September 15, 2022.

On GovTribe

See Tmtrx, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login